top of page
EXCAAPE
EVALUATION OF RADIUM-223 ACTIVITY IN ASYMPTOMATIC PATIENTS WITH mCRPC WHILE ON ABIRATERONE OR ENZALUTAMIDE BESIDES AR-V7 STATUS
CLINICAL TRIAL DETAILS
TO EVALUATE RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (rPFS) OF RADIUM-223 (223Ra) FOR THE TREATMENT OF ASYMPTOMATIC METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PATIENTS WITH BONE METASTASES AND NO VISCERAL INVOLVEMENT WHO HAD PREVIOUSLY PROGRESSED ON ABIRATERONE ACETATE OR ENZALUTAMIDE.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
PROSTATE
9
52
II
Spain
Closed
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
EXCAAPE Trial Published in the European Journal of Cancer
Dr. Joan Carles Galcerán presents results from the EXCAAPE clinical trial at ESMO 2020
MEDSIR to present results of two of our research projects this year at ESMO 2020!
TRIAL SITES
Hospital Universitario Vall d'Hebron (Spain)
Hospital Clínic de Barcelona (Spain)
Hospital Universitario Ramón y Cajal (Spain)
Hospital Reina Sofía (Spain)
Hospital San Pedro Alcántara (Spain)
Hospital Parc Taulí (Spain)
Instituto Catalán de Oncología de Hospitalet (ICO) (Spain)
Hospital Lucus Augusti (Spain)
Hospital Universitari Son Espases (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page